melanoma

Highlight Therapeutics trials second-line melanoma combo after immunotherapy fails
Pharmaforum
Wed, 09/2/20 - 10:49 am
Highlight Therapeutics
melanoma
BO-112
Keytruda
Merck
FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma
Pharmaceutical Business Review
Mon, 08/3/20 - 10:33 am
Roche
FDA
Tecentriq
Cotellic
Zelboraf
melanoma
Regeneron pairs with BioNTech on melanoma immunotherapy
Pharmaforum
Mon, 08/3/20 - 10:15 am
Regeneron
BioNTech
melanoma
Libtayo
vaccines
BNT111
MRNA
Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge
Pharmaforum
Fri, 07/31/20 - 10:43 am
Roche
Tecentriq
FDA
melanoma
Bristol-Myers Squibb
Merck
AACR: Roche's Tecentriq, added to Cotellic and Zelboraf, stalls melanoma progression
Fierce Pharma
Mon, 04/27/20 - 09:47 am
Roche
Tecentriq
Cotellic
Zelboraf
melanoma
AACR
Elios Therapeutics presents new Phase IIb data for personalized cancer vaccine in high-risk melanoma patients
Pharmaceutical Business Review
Mon, 02/10/20 - 11:35 pm
Elios Therapeutics
clinical trials
vaccines
melanoma
Immuno-oncology combination for melanoma using Nektar drug boosts cell therapy in mice
Fierce Biotech
Fri, 01/31/20 - 12:11 pm
melanoma
Nektar Therapeutics
bempegaldesleukin
Nektar shows durability of Opdivo combo in 18-month update
Fierce Biotech
Mon, 11/11/19 - 10:53 am
Nektar Therapeutics
NKTR-214
Opdivo
Bristol-Myers Squibb
melanoma
clinical trials
Led by BioNTech, six biotechs line up for October IPOs
Endpoints
Sat, 09/28/19 - 04:38 pm
IPOs
MRNA
melanoma
inebilizumab
NMOSD
blood cancer
solid tumors
BioNTech
ADC Therapeutics
Viela Bio
Frequency Therapeutics
Aprea Therapeutics
Monopar Therapeutics
Skin Cancer Diagnostics Company Files for $57 Million IPO
CP Wire
Thu, 06/27/19 - 09:57 am
Castle Biosciences
melanoma
IPOs
diagnostics
Skin Cancer Diagnostics Company Files for $57 Million IPO
Thu, 06/27/19 - 09:57 am
Castle Biosciences
melanoma
IPOs
diagnostics
Complete response rate in Nektar melanoma trial hits 34%
Fierce Biotech
Sun, 06/2/19 - 01:12 pm
Nektar
NKTR-214
Opdivo
ASCO 2019
melanoma
Keytruda gets okay from FDA for adjuvant melanoma
Pharmaforum
Wed, 02/20/19 - 09:49 am
FDA
Merck
adjuvant melanoma
melanoma
Keytruda
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Yahoo/Benzinga
Sun, 02/10/19 - 11:08 pm
Motif Biosciences
Iclaprim
Merck
Keytruda
melanoma
JNJ
esketamine
ASCO
Pfizer
Veru. earnings
Aveo Pharmaceuticals
Calithera Biosciences
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
Fri, 12/21/18 - 12:10 pm
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Merck bags adjuvant okay for Keytruda in melanoma
Pharmaforum
Tue, 12/18/18 - 10:13 am
Merck
Europe
Keytruda
melanoma
OncoSec’s defense of weak preliminary Tavo data for PD-1 resistant melanoma can’t stop a rout
Endpoints
Tue, 11/6/18 - 11:52 pm
OncoSec
Merck
Keytruda
Tavo
melanoma
Immunotherapy Drugs Slow Skin Cancer That Has Spread to the Brain
New York Times, NY
Thu, 08/23/18 - 11:19 am
melanoma
Opdivo
clinical trials
Bristol-Myers Squibb
Opdivo Approved in Europe for Additional Use in Melanoma Patients
CP Wire
Tue, 07/31/18 - 10:12 am
Opdivdo
Bristol-Myers Squibb
melanoma
advanced melanoma
Europe
Opdivo Approved in Europe for Additional Use in Melanoma Patients
Tue, 07/31/18 - 09:29 am
Opdivdo
Bristol-Myers Squibb
melanoma
advanced melanoma

Pages